JY
PRQR icon

Jeff Yass’s ProQR Therapeutics PRQR Stock Holding History

Jeff Yass’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-18,400
Closed -$48.8K – 13244
2024
Q4 		$48.8K Buy
18,400
+2,800
+18% +$8.89K ﹤0.01% 11688
2024
Q3 		$28.4K Buy
+15,600
New +$29.3K ﹤0.01% 11544
2023
Q2 		– Sell
-118,100
Closed -$252K – 12909
2023
Q1 		$252K Buy
118,100
+83,200
+238% +$254K ﹤0.01% 10105
2022
Q4 		$129K Buy
+34,900
New +$45.7K ﹤0.01% 10678
2022
Q2 		– Sell
-19,100
Closed -$17K – 13712
2022
Q1 		$17K Buy
19,100
+4,300
+29% +$14.4K ﹤0.01% 12668
2021
Q4 		$119K Sell
14,800
-42,700
-74% -$325K ﹤0.01% 12007
2021
Q3 		$481K Buy
+57,500
New +$376K ﹤0.01% 9492
2021
Q2 		– Sell
-97,000
Closed -$641K – 13108
2021
Q1 		$641K Buy
+97,000
New +$496K ﹤0.01% 8895

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Jeff Yass's PRQR Position: Q2 2026 in Review

Jeff Yass sold out of ProQR Therapeutics (PRQR) in Q2 2026, closing a stake of 12,206 shares — an estimated $19.8K sold.

Jeff Yass first reported a position in PRQR in Q4 2017 and held it in 19 quarters. The position peaked at $1.07M in Q3 2021. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

  • Jeff Yass reported no remaining ProQR Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 12,206 ProQR Therapeutics shares in Q2 2026, an estimated $19.8K.
  • Jeff Yass first reported a position in ProQR Therapeutics in Q4 2017 and held it in 19 quarters.
  • Jeff Yass's ProQR Therapeutics position peaked at $1.07M in Q3 2021.
  • 70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.